Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 2/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 2/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Boldine SCHEMBL29973042 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL7387149 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL13459203 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL177550 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL30184400 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL3060583 | 0.99 | ALDH1A1 (0.98) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Predicentrine SCHEMBL25844649 | 0.95 | ALDH1A1 (0.91) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Predicentrine SCHEMBL4410538 | 0.95 | ALDH1A1 (0.91) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| Boldine SCHEMBL420488 | 0.94 | ALDH1A1 (0.89) | ALDH1A1HSD17B10HPGDKDM4EMAPT | |
| SCHEMBL30475142 | 0.94 | HTR7 (1.00) | ALDH1A1HSD17B10HPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 905 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | claimed |
| US-20250057962-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2025-02-20 | — | — | US | claimed |
| CN-118703454-A | Cytochrome P450 enzyme from stephania tetrandra and application thereof in biosynthesis of aporphine alkaloid compound | 中国中医科学院中药研究所 | 2024-09-27 | — | — | CN | claimed |
| EP-4426712-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | Ripple Therapeutics Corporation (CA) | 2024-09-11 | — | — | EP | claimed |
| CN-118547022-A | Preparation method of aporphine alkaloid compound and related catalytic enzyme and application thereof | 中国中医科学院中药研究所 | 2024-08-27 | — | — | CN | claimed |
| US-20240261252-A1 | Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. | HELDRETH JR DAVID ALAN (US) | 2024-08-08 | — | — | US | claimed |
| US-20230279170-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2023-09-07 | — | — | US | claimed |
| CN-113801843-B | Method for enhancing human urine-derived stem cell stem property | 北京中医药大学 | 2023-06-30 | — | — | CN | claimed |
| WO-2023079362-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-05-11 | — | — | WO | claimed |
| CN-115916142-A | Coupled terpene conjugates | 埃里格实验室公司 | 2023-04-04 | — | — | CN | claimed |
| EP-1117376-A1 | USE OF A BOLDO EXTRACT IN A COSMETIC OR DERMATOLOGICAL PRODUCT | LABORATOIRES SEROBIOLOGIQUES (FR) | 2001-07-25 | — | — | EP | claimed |
| WO-2000059466-A1 | COSMETIC COMPOSITION COMPRISING A LIPID SKELETONEMA EXTRACT | LVMH RECHERCHE (FR) | 2000-10-12 | — | — | WO | claimed |
| WO-2000019973-A1 | USE OF A BOLDO EXTRACT IN A COSMETIC OR DERMATOLOGICAL PRODUCT | COGNIS FRANCE, S.A. (FR) | 2000-04-13 | — | — | WO | claimed |
| EP-0592622-B1 | EXTENSION OF EDIBLE OIL LIFETIME USING ACTIVATED CARBONS | CALGON CARBON CORP (US) | 1997-06-25 | — | — | EP | claimed |
| CN-1103863-A | Secoaporphine compound, its preparation method and medicinal composition containing said compound | SU MINGJIA (CN) | 1995-06-21 | — | — | CN | claimed |
| US-5348755-A | Extension of edible oil lifetime using activated carbons | CALGON CARBON CORPORATION (US) | 1994-09-20 | — | — | US | claimed |
| EP-0592622-A4 | — | — | 1994-08-03 | — | — | EP | claimed |
| EP-0592622-A1 | EXTENSION OF EDIBLE OIL LIFETIME USING ACTIVATED CARBONS. | CALGON CARBON CORP (US) | 1994-04-20 | — | — | EP | claimed |
| WO-1993017567-A1 | EXTENSION OF EDIBLE OIL LIFETIME USING ACTIVATED CARBONS | CALGON CARBON CORPORATION (US) | 1993-09-16 | — | — | WO | claimed |
| US-4185119-A | Antiallergic methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057962-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | CCND2, CCND1, C9 | ALDH1A1 2326/4885HSD17B10 878/4885HPGD 308/4885 |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | MEF2D, TEAD2, TEAD1 | ALDH1A1 2530/4885HSD17B10 1871/4885HPGD 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.